Bretovameran

Pre-clinicalActive
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

COVID-19 Vaccination

Conditions

COVID-19 Vaccination

Trial Timeline

Oct 11, 2024 → Dec 30, 2026

About Bretovameran

Bretovameran is a pre-clinical stage product being developed by Pfizer for COVID-19 Vaccination. The current trial status is active. This product is registered under clinical trial identifier NCT06613984. Target conditions include COVID-19 Vaccination.

What happened to similar drugs?

7 of 20 similar drugs in COVID-19 Vaccination were approved

Approved (7) Terminated (4) Active (11)

Hype Score Breakdown

Clinical
3
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06613984Pre-clinicalActive

Competing Products

20 competing products in COVID-19 Vaccination

See all competitors
ProductCompanyStageHype Score
mRNA-1283.251 Variant-containing FormulationModernaApproved
0
mRNA-1283.222ModernaPhase 3
0
COVID-19 VaccineModernaPreclinical
0
mRNA-1083ModernaPhase 3
0
SPIKEVAX (mRNA-1273)ModernaPreclinical
0
Moderna COVID-19 VaccineModernaPreclinical
0
Gam-COVID-VacDr. Reddy's LaboratoriesPhase 2/3
31
Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboSinopharmPhase 2
31
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
29
Gimsilumab + PlaceboRoivant SciencesPhase 2
32
Icosapent ethylAmarin CorporationPhase 2
25
Bamlanivimab + Placebo + EtesevimabEli LillyPhase 3
40
InfliximabCelltrionPhase 2
35
CT-P63 and CT-P66 / PlaceboCelltrionPhase 3
32
Enzalutamide PillAstellas PharmaPhase 2
27
S-892216 + PlaceboShionogiPhase 2
35
S-892216 + CarbamazepineShionogiPhase 1
29
FOY-305 + PlaceboOno PharmaceuticalPhase 3
40
DesidustatZydus LifesciencesPhase 2
35
LY3819253 + PlaceboEli LillyPhase 1
29